Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

References

• AdamsMMontagueCTPrinsJBActivators of PPAR-gamma have depot-specific effects on human preadipocyte diffentiationJ Clin Invest19971003149539399962
   PubMed Web of Science ®Google Scholar
• BakrisFLDoleJFPorterLERosiglitazone improves blood pressure in patients with type 2 diabetes mellitusDiabetes200049A96
   Web of Science ®Google Scholar
• BaysHMandarinoLDeFronzoRARole of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferators-activated receptor agonists provide a rational therapeutic approachJ Clin Endocrinol Metab2004894637814764748
   PubMed Web of Science ®Google Scholar
• BennettSMAgrawalAElashaHRosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose toleranceDiabet Med2004214152215089784
   PubMed Web of Science ®Google Scholar
• BhatiaVViswanathanPInsulin resistance and PPAR insulin sensitizersCurr Opin Investig Drugs200678917
   PubMedGoogle Scholar
• BlaschkeFCaglayanEHsuehWAPeroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetesEndocrinol Metab Clin North Am2006355617416959586
   PubMed Web of Science ®Google Scholar
• BodenGZhangMRecent findings concerning thiazolidinediones in the treatment of diabetesExpert Opin Invest Drugs20061524350
   PubMed Web of Science ®Google Scholar
• BuchananTAXiangAHPetersRKPreservation of pancreatic beta-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high risk hispanic womenDiabetes200251279680312196473
   PubMed Web of Science ®Google Scholar
• CampHSThiazolidinediones in diabetes: current status and future outlookCurr Opin in Investig Drugs2003440611
   PubMedGoogle Scholar
• ChawlaALeeCHBarakYPPARdelta is a very low-density lipoprotein sensor in macrophagesProc Natl Acad Sci USA200310012687312540828
   PubMed Web of Science ®Google Scholar
• De VosPLefebvreAMMillerSGThiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor-gammaJ Clin Invest199698100498770873
   PubMed Web of Science ®Google Scholar
• DiamantMHeineRJThiazolidinediones in type 2 diabetes mellitus: current clinical evidenceDrugs200363137340512825962
   PubMed Web of Science ®Google Scholar
• DiepQNEl MabroukMCohnJSStructure, endothelial function, cell growth, and inflammation in blood vassels of angiotensina II-infused rats: role of peroxisome proliferator-acvtivated receptor-gammaCirculation2002105229630212010913
   PubMed Web of Science ®Google Scholar
• DurbinRJThiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin rsistanceDiabetes Obes Metab20046280515171752
   PubMed Web of Science ®Google Scholar
• EinhornDRendellMRosenzweigJFor the pioglitazone 027 study group: pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled studyClin Ther200022139540911192132
   PubMed Web of Science ®Google Scholar
• EmotoMAnnoTSatoYTroglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytesDiabetes20015011667011334422
   PubMed Web of Science ®Google Scholar
• ErdmannEDormandyJACharbonnelBThe effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) StudyJAm Coll Cardiol20074917728017466227
   PubMed Web of Science ®Google Scholar
• FhillipsLSGrunbergerGMillerEfor the Rosiglitazone Clinical Trials Study GroupOnce- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetesDiabetes Care2001243081511213884
   PubMed Web of Science ®Google Scholar
• FonsecaVRosenstockJPatwardhanREffect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trialJAMA2000283169570210755495
   PubMed Web of Science ®Google Scholar
• GersteinHCYusufSHolmanRThe DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trialDiabetologia20044715192715322749
   PubMed Web of Science ®Google Scholar
• GhanimHGargRAljadaASuppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obeseJ Clin Endocrinol Metab20018613061211238525
   PubMed Web of Science ®Google Scholar
• GinsbergHNZhangYLHernandez-OnoARegulation of plasma triglycerides in insulin resistance and diabetesArch Med Res2005362324015925013
   PubMed Web of Science ®Google Scholar
• GlintborgDStovingRKHagenCPioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndromeJ Clin Endocrinol Metab20059056051216076946
   PubMed Web of Science ®Google Scholar
• GoyaKSumitaniSOtsukiMThe thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cellsJ Diabetes Complications2006203364216949522
   PubMed Web of Science ®Google Scholar
• GrinsellJWLardinoisCKSwislockiAPioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive ratA J Hypertens2000133705
   PubMed Web of Science ®Google Scholar
• HaffnerSMGreenbegASWestonWMEffects of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitusCirculation20021066798412163427
   PubMed Web of Science ®Google Scholar
• HanK-HChangMKBoullierAOxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptorJ Clin Invest200010679380210995790
   PubMed Web of Science ®Google Scholar
• HofmannCLorenzKBraithwaiteSSAltered gene expression for tumor necrosis factor-alfa and its receptor during drug and dietary modulation of insulin resistanceEndocrinology1994134264708275942
   PubMed Web of Science ®Google Scholar
• HorioTSuzukiMTakamisawaIPioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertensionAm J Hypertens20051816263016364837
   PubMed Web of Science ®Google Scholar
• IglarzMTouyzRMAmiriFEffect of peroxisome proliferator-activated receptor-delta and-gamma activators on vascular remodelling in endothelin-dependent hypertensionArterioscler Thromb Vasc Biol200323455112524223
   PubMed Web of Science ®Google Scholar
• IppEImpaired glucose tolerance: the irrepressible alpha-cell?Diabetes Care2000235697010834408
   PubMed Web of Science ®Google Scholar
• IshibashiMEgashiraKHiasaKAntiinflammatory and antiarteriosclerotic effects of pioglitazoneHypertension2002406879312411463
   PubMed Web of Science ®Google Scholar
• JarvinenHThiazolidinedionesN Engl J Med200435111061815356308
   PubMed Web of Science ®Google Scholar
• KhanMASt PeterJVXueJLA prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazoneDiabetes Care2002257081111919129
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAADOPT Study GroupGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyNEngl J Med2006355242743
   PubMed Web of Science ®Google Scholar
• KliewerSALehmannJMMilburnMVThe PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signalling pathwaysRecent Prog Horm Res1999543456710548883
   PubMedGoogle Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of Type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• LebovitzHEDoleJFPatwardhanRRosiglitazone monotherapy is effective in patients with type 2 diabetesJ Clin Endocrinol Metab200186280811232013
   PubMed Web of Science ®Google Scholar
• LehmannJMMcKeeDDWatsonMAThe human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactionsJ Clin Invest199810210161239727070
   PubMed Web of Science ®Google Scholar
• LimHDeySKPPAR delta functions as a prostacyclin receptor in blastocyst implantationTrends Endocrinol Metab2000111374210754535
   PubMed Web of Science ®Google Scholar
• MaedaNTakahashiMFunahashiTPPAR-gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived proteinDiabetes2001502094911522676
   PubMed Web of Science ®Google Scholar
• MalinowskiJMBolestaSRosiglitazone in the treatment of type 2 diabetes mellitus: a critical reviewClin Ther20002211516811110228
   PubMed Web of Science ®Google Scholar
• MillerRCPeltonJTHugginsJPEndothelins: from receptors to medicineTrends Pharmacol Sci1993254608480375
   PubMedGoogle Scholar
• MiyazakiYMahankaliAMatsudaMImproved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazoneDiabetes Care2001247101911315836
   PubMed Web of Science ®Google Scholar
• MontagueCTO’RahillySThe perils of portiliness: causes and consequences of visceral adiposityDiabetes200049883810866038
   PubMed Web of Science ®Google Scholar
• MoriYMurakawaYOkadaKEffect of troglitazone on body fat distribution in type 2 diabetic patientsDiabetes Care1999229081210372240
   PubMed Web of Science ®Google Scholar
• NakamuraTFunahashiTYamashitaSThiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trialDiabetes Res Clin Pract2001541819011689273
   PubMed Web of Science ®Google Scholar
• NataliABaldewegSToschiERosiglitazone directly improves endothelial function in type 2 diabetic patientsDiabetes200251Suppl 2P-573A142
   Google Scholar
• NestoRWBellDBonowROFonsecaVThiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes AssociationCirculation20031082941814662691
   PubMed Web of Science ®Google Scholar
• NiemeyerNVJanneyLMThiazolidinedione-induced edemaPharmacotherapy200222924912126225
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med200735624577117517853
   PubMed Web of Science ®Google Scholar
• OakesNDThalenPGJacintoSMThiazolidinediones increase plasma adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availabilityDiabetes20015011586511334421
   PubMed Web of Science ®Google Scholar
• OgiharaTRakugiHIkegamiHEnhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensivesAm J Hypertens19958316207794582
   PubMed Web of Science ®Google Scholar
• OkunoATamemotoHTobeKTroglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker ratsJ Clin Invest19981011354619502777
   PubMed Web of Science ®Google Scholar
• OliverWRJrShenkJLSnaithMRSelective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transportProc Natl Acad Sci USA20019853061111309497
   PubMed Web of Science ®Google Scholar
• ParulkarAAPendergrassMLGranda-AyalaRNonhypoglycemic effects of thiazolidinedionesAnn Intern Med200113530711511161
   PubMed Web of Science ®Google Scholar
• PetersJMLeeSLiWGrowth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferators activated receptor beta (delta)Mol Cell Biol20002051192810866668
   PubMed Web of Science ®Google Scholar
• PanXRLiGWHuYHEffects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes StudyDiabetes Care199720537449096977
   PubMed Web of Science ®Google Scholar
• ParulkarAAPendergrassMLGranda-AyalaRNonhypoglycemic effects of thiazolidinedionesAnn Intern Med2001134617111187421
   PubMed Web of Science ®Google Scholar
• PasceriVWuHWillersenJYehEModular of vascular inflammation in vitro and in vivo by peroxisome proliferator activated receptor- activatorsCirculation2001101235810645917
   PubMed Web of Science ®Google Scholar
• PatelJAndersonRJRappaportEBRosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo controlled studyDiabetes Obes Metab199911657211220295
   PubMed Web of Science ®Google Scholar
• PerryCGPetrieJRInsulin-sensitising agents:beyond thiazolidinedionesExpert Opin Emerg Drugs200271657415989542
   PubMedGoogle Scholar
• PistroschFPassauerJFischerSIn type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose controlDiabetes Care2004274849014747233
   PubMed Web of Science ®Google Scholar
• PistroschFHerbringKOelschlaegelUPPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cellsAtherosclerosis2005183163715907852
   PubMed Web of Science ®Google Scholar
• PsatyBMFurbergCDThe record on rosiglitazone and risk of myocardial infarctionN Engl J Med200735767917551162
   PubMed Web of Science ®Google Scholar
• RaskinPRappaportEBColeSTRosiglitazone short term monotheraphy lowers fasting and postprandial glucosze in patients with type 2 diabetesDiabetologia2000432788410768088
   PubMed Web of Science ®Google Scholar
• RedondoSHristovMGumbelDBiphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-gamma and transforming growth factor-beta 1Thromb Haemost2007979798717549301
   PubMed Web of Science ®Google Scholar
• RichterBBandeira-EchtlerEBergerhoffKPioglitazone for type 2 diabetes mellitusCochrane Database Syst Rev200618CD00606017054272
   PubMedGoogle Scholar
• RobertsAWThomasAReesAPeroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directionsCurr Opin Lipidol2003145677314624133
   PubMed Web of Science ®Google Scholar
• RomualdiDGuidoMCiampelliMSelective effects of pioglitazone on insulin androgen abnormalities in normo- and hyperinsulineamic obese patients with polycystic ovary sindromeHum Reprod20031812101812773448
   PubMed Web of Science ®Google Scholar
• RosenstckJEinhornDHershonKthe pioglitazone 014 study groupEfficay and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin theraphyInt J Clin Pract200256251712074206
   PubMed Web of Science ®Google Scholar
• SatohHTsukamotoKHashimotoYThiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR on vascular endothelial functionBiochem Biophys Res Commun1999254757639920814
   PubMed Web of Science ®Google Scholar
• ScheenAJThiazolidinediones and liver toxicityDiabetes Metab2001273051311431595
   PubMed Web of Science ®Google Scholar
• SchiffrinELAmiriFBenkiraneKPeroxisome proliferator-activated receptors: vascular and cardic effects in hypertensionHypertension200342664812874098
   PubMedGoogle Scholar
• SekinoNKashiwabaraAInoueTUsefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemiaDiabetes Obes Metab20035145912681020
   PubMed Web of Science ®Google Scholar
• ShirakiTKamiyaNShikiSAlpha, beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gammaJ Biol Chem2005280141455315695504
   PubMed Web of Science ®Google Scholar
• SteppanCMBaileySTBhatSThe hormone resistin links obesity to diabetesNature20014093071211201732
   PubMed Web of Science ®Google Scholar
• StumvollMThiazolidinediones- some recent developmentsExpert Opin Investig Drugs200312117987
   PubMed Web of Science ®Google Scholar
• TanNSMichalinLNoyNCritical roles of PPAR beta/delta in keratinocyte response to inflammationGenes Dev20011532637711751632
   PubMed Web of Science ®Google Scholar
• TolmanKGThiazolidinedione hepatotoxicity: a class effect?Int J Clin Pract2000113Suppl2934
   Google Scholar
• TsaiYSMaedaNPPAR-gamma: a critical determinant of body fat distribution in humans and miceTrends Cardiovasc Med20051581516039966
   PubMed Web of Science ®Google Scholar
• TuomilehtoJLindstromJErikssonJCPrevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose toleranceN Engl J Med200134413435011333990
   PubMed Web of Science ®Google Scholar
• TurnerNCClaphamJCInsulin resistance, impaired glucose tolerance and non-insulin dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilitiesProg Drug Res19985133949949859
   PubMedGoogle Scholar
• UngerRHOrciLDiseases of liporegulation: new perspective on obesity and related disordersFASEB J2001153122111156947
   PubMed Web of Science ®Google Scholar
• VasudevanARBalasubramanyamAThiazolidinediones: a review of their mechanism of insulin sensitiziation, therapeutic potential, clinical efficacy, and tolerabilityDiabetes Technol Ther200468506315684639
   PubMedGoogle Scholar
• WangNVernaLChenN-GConstitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cellsJ Biol Chem2002277341768112107164
   PubMed Web of Science ®Google Scholar
• WangYXLeeCHTiepSPeroxisome-prolifator-activated receptor delta activates fat metabolism to prevent obesityCell20031131597012705865
   PubMed Web of Science ®Google Scholar
• WangCHCilibertiNLiSHRosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropyCirculation2004109139240014993120
   PubMed Web of Science ®Google Scholar
• WidlanskyMEGokceNKeaneyJFJrThe clinical implications of endothelial dysfunctionJ Am Coll Cardiol20034211496014522472
   PubMed Web of Science ®Google Scholar
• WilcoxRBousserMGBetteridgeDJEffects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)Stroke2007388657317290029
   PubMed Web of Science ®Google Scholar
• WillsonTMBrownPJSternbachDDThe PPARs: fro orphan receptors to drug discoveryJ Med Chem2000435275010691680
   PubMed Web of Science ®Google Scholar